Objective: Stimulant-drugs are effective for treating attention-deficit/hyperactivity disorder (ADHD), yet discontinuation and switch to non-stimulant ADHD-drugs is common. This study aimed to identify genetic, clinical and socio-demographic factors influencing stimulant-treatment initiation, discontinuation and switch to non-stimulants in individuals ADHD.
Methods:We obtained genetic and national-register data for 9,133 individuals with ADHD from the Danish iPSYCH2012 sample, and defined stimulant-treatment initiation, discontinuation and switch from prescriptions. For each stimulant-treatment outcome, we examined associations with polygenic risk scores (PRSs) for psychiatric disorders, clinical, and socio-demographic factors using survival analyses, and conducted genome-wide association studies (GWASs) and estimated SNP-heritabilities (h 2 SNP).Results: 81% initiated stimulant-treatment. Within two years, 45% discontinued stimulants and 15% switched to non-stimulants. Bipolar-PRS (hazard ratio[HR]=1.05, 95%confidence interval[CI]=1.02-1.09) and schizophrenia-PRS (HR=1.07,95%CI=1.03-1.11) were associated with discontinuation. Depression, bipolar and schizophrenia PRSs were marginally associated with switch (HRrange=1.05-1.07) with CIs including one. No associations were observed for ADHD-PRS and autism-PRS. Individuals diagnosed with ADHD ≥13 years-of-age had higher rates of stimulant initiation, discontinuation, and switch (HRrange=1.27-2.01). Psychiatric comorbidities generally reduced rates of initiation (HRrange=0.84-0.88), and increased rates of discontinuation (HRrange=1.19-1.45) and switch (HRrange=1.40-2.08). Estimated h 2 SNP were not significantly different from zero. No GWAS-hits were identified for stimulant initiation or discontinuation. A locus on chromosome 16q23.3 reached genome-wide significance for switch (p=4.7×10 −8 ).
Conclusion:Our findings suggest that individuals with ADHD with higher polygenic liability for mood/psychotic disorders, delayed ADHD diagnosis, and psychiatric comorbidities have higher risk for 4 stimulant-treatment discontinuation and switch to non-stimulants. Despite limited sample size, one possible GWAS-hit for switch was identified, illustrating the potential of utilizing prescription databases in pharmacogenomics.